Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

Aldina Pivodic; Helena Johansson; Lois EH Smith; Chatarina Löfqvist; Kerstin Albertsson-Wikland; Staffan Nilsson; Ann Hellström

doi:10.1136/bmjophth-2021-000923

Pivodic, Aldina; Johansson, Helena; Smith, Lois EH; Löfqvist, Chatarina; Albertsson-Wikland, Kerstin; Nilsson, Staffan; Hellström, Ann

2022-04-08 00:00:00

ObjectiveThe current grading of retinopathy of prematurity (ROP) does not sufficiently discriminate disease severity for evaluation of trial interventions. The published ROP Activity Scales (original: ROP-ActS and modified: mROP-ActS), describing increasing severity of ROP, versus the categorical variables severe ROP, stage, zone and plus disease were evaluated as discriminators of the effect of an ROP preventive treatment.Methods and analysisThe Mega Donna Mega trial investigated ROP in infants born <28-week gestational age (GA), randomised to arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation or no supplementation. Of 207 infants, 86% with finalised ROP screening were included in this substudy. ROP-ActS versus standard variables were evaluated using Fisher’s non-parametric permutation test, multivariable logistic and linear regression and marginal fractional response models.ResultsThe AA:DHA group (n=84) and the control group (n=93) were well balanced. The maximum ROP-ActS measurement was numerically but not significantly lower in the AA:DHA group (mean: 4.0 (95% CI 2.9 to 5.0)) versus the control group (mean: 5.3 (95% CI 4.1 to 6.4)), p=0.11. In infants with any ROP, the corresponding scale measurements were 6.8 (95% CI 5.4 to 8.2) and 8.7 (95% CI 7.5 to 10.0), p=0.039. Longitudinal profiles of the scale were visually distinguished for the categories of sex and GA for the intervention versus control.ConclusionsThe preventive effect of AA:DHA supplementation versus no supplementation was better discriminated by the trial’s primary outcome, severe ROP, than by ROP-ActS. The sensitivity and the linear qualities of ROP-ActS require further validations on large data sets and perhaps modifications.Trial registration numberNCT03201588.

http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Veterinary Record Case Reports British Medical Journal

http://www.deepdyve.com/lp/british-medical-journal/evaluation-of-the-retinopathy-of-prematurity-activity-scale-rop-acts-Mg1LComHx0

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

$ObjectiveThe current grading of retinopathy of prematurity (ROP) does not sufficiently discriminate disease severity for evaluation of trial interventions. The published ROP Activity Scales (original: ROP-ActS and modified: mROP-ActS), describing increasing severity of ROP, versus the categorical variables severe ROP, stage, zone and plus disease were evaluated as discriminators of the effect of an ROP preventive treatment.Methods and analysisThe Mega Donna Mega trial investigated ROP in infants born <28-week gestational age (GA), randomised to arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation or no supplementation. Of 207 infants, 86% with finalised ROP screening were included in this substudy. ROP-ActS versus standard variables were evaluated using Fisher’s non-parametric permutation test, multivariable logistic and linear regression and marginal fractional response models.ResultsThe AA:DHA group (n=84) and the control group (n=93) were well balanced. The maximum ROP-ActS measurement was numerically but not significantly lower in the AA:DHA group (mean: 4.0 (95% CI 2.9 to 5.0)) versus the control group (mean: 5.3 (95% CI 4.1 to 6.4)), p=0.11. In infants with any ROP, the corresponding scale measurements were 6.8 (95% CI 5.4 to 8.2) and 8.7 (95% CI 7.5 to 10.0), p=0.039. Longitudinal profiles of the scale were visually distinguished for the categories of sex and GA for the intervention versus control.ConclusionsThe preventive effect of AA:DHA supplementation versus no supplementation was better discriminated by the trial’s primary outcome, severe ROP, than by ROP-ActS. The sensitivity and the linear qualities of ROP-ActS require further validations on large data sets and perhaps modifications.Trial registration numberNCT03201588.$

References (45)

M. Norman, B. Hallberg, T. Abrahamsson, L. Björklund, M. Domellöf, A. Farooqi, C. Bruun, Christian Gadsbøll, L. Hellström-Westas, Fredrik Ingemansson, K. Källén, D. Ley, K. Maršál, E. Normann, F. Serenius, O. Stephansson, L. Stigson, Petra Um-Bergström, S. Håkansson (2019)

Association Between Year of Birth and 1-Year Survival Among Extremely Preterm Infants in Sweden During 2004-2007 and 2014-2016

JAMA, 321

C. Löfqvist, S. Najm, G. Hellgren, E. Engström, K. Sävman, A. Nilsson, M. Andersson, A. Hård, Lois Smith, A. Hellström (2018)

Association of Retinopathy of Prematurity With Low Levels of Arachidonic Acid

JAMA Ophthalmology, 136

(Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179–201. 10.1016/S0031-3955(16)34975-63081865)

Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179–201. 10.1016/S0031-3955(16)34975-63081865

Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179–201. 10.1016/S0031-3955(16)34975-63081865, Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179–201. 10.1016/S0031-3955(16)34975-63081865

A. Hellström, A. Nilsson, D. Wackernagel, A. Pivodic, M. Vanpee, Ulrika Sjöbom, G. Hellgren, B. Hallberg, M. Domellöf, S. Klevebro, William Hellström, M. Andersson, Anna-My Lund, C. Löfqvist, A. Elfvin, K. Sävman, I. Hansen-Pupp, A. Hård, Lois Smith, D. Ley (2021)

Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity

JAMA Pediatrics, 175

A. Pivodic, S. Nilsson, A. Stahl, Lois Smith, A. Hellström (2020)

Validation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) using retrospective clinical data

Acta ophthalmologica, 99

Isaac Ben-Sira, A. Deutman, H. Fledelius, J. Flynn, A. Garner, Chairman., G. Gole, N. Hindle, H. Ideta, J. Kingham, F. Koerner, W. Konen, A. Majima, A. Mccormick, A. Mushin, I. Nissenkorn, E. Palmer, G. Quinn, Arthur Rosenhaum, D. Schaffer, D. Stark, B. Svedbergh, K. Tan, Yasuhiko Tanaka (2004)

An international classification of retinopathy of prematurity.

British Journal of Ophthalmology, 68

Z. Fu, Chatarina Lofqvist, Z. Shao, Ye Sun, Jean-Sébastien Joyal, Christian Hurst, Ricky Cui, L. Evans, Katherine Tian, J. Sangiovanni, Jing Chen, D. Ley, I. Pupp, A. Hellstrom, Lois Smith (2015)

Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin.

The American journal of clinical nutrition, 101 4

(Gunn TR, Easdown J, Outerbridge EW, et al. Risk factors in retrolental fibroplasia. Pediatrics 1980;65:1096–100. 10.1542/peds.65.6.10966892851)

Gunn TR, Easdown J, Outerbridge EW, et al. Risk factors in retrolental fibroplasia. Pediatrics 1980;65:1096–100. 10.1542/peds.65.6.10966892851

Gunn TR, Easdown J, Outerbridge EW, et al. Risk factors in retrolental fibroplasia. Pediatrics 1980;65:1096–100. 10.1542/peds.65.6.10966892851, Gunn TR, Easdown J, Outerbridge EW, et al. Risk factors in retrolental fibroplasia. Pediatrics 1980;65:1096–100. 10.1542/peds.65.6.10966892851

M. Walsh, R. Kliegman (1986)

Necrotizing Enterocolitis: Treatment Based on Staging Criteria

Pediatric Clinics of North America, 33

(Löfqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2018;136:271–7. 10.1001/jamaophthalmol.2017.665829423508)

Löfqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2018;136:271–7. 10.1001/jamaophthalmol.2017.665829423508, Löfqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol 2018;136:271–7. 10.1001/jamaophthalmol.2017.665829423508

A. Hellström, A. Hård (2019)

Screening and novel therapies for retinopathy of prematurity - A review.

Early human development

(Ich topic E 9 statistical principles for clinical trials. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf [Accessed 21 May 2021].)

Ich topic E 9 statistical principles for clinical trials. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf [Accessed 21 May 2021]., Ich topic E 9 statistical principles for clinical trials. Available: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf [Accessed 21 May 2021].

(International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991–9. 10.1001/archopht.123.7.99116009843)

International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991–9. 10.1001/archopht.123.7.99116009843, International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991–9. 10.1001/archopht.123.7.99116009843

(Norman M, Hallberg B, Abrahamsson T, et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004-2007 and 2014-2016. JAMA 2019;321:1188–99. 10.1001/jama.2019.202130912837)

Norman M, Hallberg B, Abrahamsson T, et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004-2007 and 2014-2016. JAMA 2019;321:1188–99. 10.1001/jama.2019.202130912837, Norman M, Hallberg B, Abrahamsson T, et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004-2007 and 2014-2016. JAMA 2019;321:1188–99. 10.1001/jama.2019.202130912837

A Hellström, AK Nilsson, D Wackernagel (2021)

Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial

, 175

M. Bernabe-García, R. Villegas-Silva, Astrid Villavicencio-Torres, P. Calder, M. Rodríguez-Cruz, J. Maldonado-Hernández, Denisse Macías-Loaiza, M. López-Alarcón, P. Inda-Icaza, L. Cruz-Reynoso (2019)

Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial.

JPEN. Journal of parenteral and enteral nutrition

(Smith LEH, Hellström A, Stahl A, et al. Development of a retinopathy of prematurity activity scale and clinical outcome measures for use in clinical trials. JAMA Ophthalmol 2019;137:305–11. 10.1001/jamaophthalmol.2018.598430543348)

Smith LEH, Hellström A, Stahl A, et al. Development of a retinopathy of prematurity activity scale and clinical outcome measures for use in clinical trials. JAMA Ophthalmol 2019;137:305–11. 10.1001/jamaophthalmol.2018.598430543348, Smith LEH, Hellström A, Stahl A, et al. Development of a retinopathy of prematurity activity scale and clinical outcome measures for use in clinical trials. JAMA Ophthalmol 2019;137:305–11. 10.1001/jamaophthalmol.2018.598430543348

M. Chiang, G. Quinn, A. Fielder, S. Ostmo, R. Chan, A. Berrocal, G. Binenbaum, M. Blair, J. Campbell, A. Capone, Y. Chen, S. Dai, A. Ells, B. Fleck, W. Good, M. Hartnett, G. Holmstrom, S. Kusaka, A. Kychenthal, D. Lepore, B. Lorenz, M. Martinez-Castellanos, Ş. Özdek, D. Ademola-Popoola, J. Reynolds, P. Shah, M. Shapiro, A. Stahl, C. Toth, A. Vinekar, L. Visser, D. Wallace, Wei-Chi Wu, Peiquan Zhao, A. Zin (2021)

International Classification of Retinopathy of Prematurity, Third Edition.

Ophthalmology

Justin Mora, Christopher Waite, C. Gilbert, Brenda Breidenstein, J. Sloper (2017)

A worldwide survey of retinopathy of prematurity screening

British Journal of Ophthalmology, 102

(Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 2021;128:e51–68. 10.1016/j.ophtha.2021.05.03134247850)

Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 2021;128:e51–68. 10.1016/j.ophtha.2021.05.03134247850

Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 2021;128:e51–68. 10.1016/j.ophtha.2021.05.03134247850, Chiang MF, Quinn GE, Fielder AR, et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 2021;128:e51–68. 10.1016/j.ophtha.2021.05.03134247850

(Bernabe-García M, Villegas-Silva R, Villavicencio-Torres A, et al. Enteral docosahexaenoic acid and retinopathy of prematurity: a randomized clinical trial. JPEN J Parenter Enteral Nutr 2019;43:874–82. 10.1002/jpen.149730614004)

Bernabe-García M, Villegas-Silva R, Villavicencio-Torres A, et al. Enteral docosahexaenoic acid and retinopathy of prematurity: a randomized clinical trial. JPEN J Parenter Enteral Nutr 2019;43:874–82. 10.1002/jpen.149730614004, Bernabe-García M, Villegas-Silva R, Villavicencio-Torres A, et al. Enteral docosahexaenoic acid and retinopathy of prematurity: a randomized clinical trial. JPEN J Parenter Enteral Nutr 2019;43:874–82. 10.1002/jpen.149730614004

(Holmström G, Hellström A, Gränse L, et al. New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 2020;104:943–9. 10.1136/bjophthalmol-2019-31487431676594)

Holmström G, Hellström A, Gränse L, et al. New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 2020;104:943–9. 10.1136/bjophthalmol-2019-31487431676594, Holmström G, Hellström A, Gränse L, et al. New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 2020;104:943–9. 10.1136/bjophthalmol-2019-31487431676594

(Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868–73. 10.1038/nm159117589522)

Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868–73. 10.1038/nm159117589522, Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868–73. 10.1038/nm159117589522

Isaac Ben-Sira (2005)

The International Classification of Retinopathy of Prematurity revisited.

Archives of ophthalmology, 123 7

(2021)

Ich topic E 9 statistical principles for clinical trials

(Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–94. 10.1001/archopht.121.12.168414662586)

Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–94. 10.1001/archopht.121.12.168414662586, Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–94. 10.1001/archopht.121.12.168414662586

K. Connor, J. Sangiovanni, Chatarina Lofqvist, C. Aderman, Jing Chen, A. Higuchi, Song Hong, Elke Pravda, Sharon Majchrzak, D. Carper, A. Hellstrom, J. Kang, E. Chew, N. Salem, C. Serhan, Lois Smith (2007)

Increased dietary intake of ω-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis

Nature Medicine, 13

(The FIREFLEYE trial. Available: https://clinicaltrials.gov/ct2/show/NCT04004208?term=NCT04004208&draw=2&rank=1 [Accessed 21 May 2021].)

The FIREFLEYE trial. Available: https://clinicaltrials.gov/ct2/show/NCT04004208?term=NCT04004208&draw=2&rank=1 [Accessed 21 May 2021].

The FIREFLEYE trial. Available: https://clinicaltrials.gov/ct2/show/NCT04004208?term=NCT04004208&draw=2&rank=1 [Accessed 21 May 2021]., The FIREFLEYE trial. Available: https://clinicaltrials.gov/ct2/show/NCT04004208?term=NCT04004208&draw=2&rank=1 [Accessed 21 May 2021].

(Swedish national guidelines for screening and management of ROP 2012, 2022. Available: https://neo.barnlakarforeningen.se/wp-content/uploads/sites/14/2014/03/ROP_2012.pdf [Accessed 28 Jan 2022].)

Swedish national guidelines for screening and management of ROP 2012, 2022. Available: https://neo.barnlakarforeningen.se/wp-content/uploads/sites/14/2014/03/ROP_2012.pdf [Accessed 28 Jan 2022].

Swedish national guidelines for screening and management of ROP 2012, 2022. Available: https://neo.barnlakarforeningen.se/wp-content/uploads/sites/14/2014/03/ROP_2012.pdf [Accessed 28 Jan 2022]., Swedish national guidelines for screening and management of ROP 2012, 2022. Available: https://neo.barnlakarforeningen.se/wp-content/uploads/sites/14/2014/03/ROP_2012.pdf [Accessed 28 Jan 2022].

(Mora JS, Waite C, Gilbert CE, et al. A worldwide survey of retinopathy of prematurity screening. Br J Ophthalmol 2018;102:9–13. 10.1136/bjophthalmol-2017-31070928855196)

Mora JS, Waite C, Gilbert CE, et al. A worldwide survey of retinopathy of prematurity screening. Br J Ophthalmol 2018;102:9–13. 10.1136/bjophthalmol-2017-31070928855196

Mora JS, Waite C, Gilbert CE, et al. A worldwide survey of retinopathy of prematurity screening. Br J Ophthalmol 2018;102:9–13. 10.1136/bjophthalmol-2017-31070928855196, Mora JS, Waite C, Gilbert CE, et al. A worldwide survey of retinopathy of prematurity screening. Br J Ophthalmol 2018;102:9–13. 10.1136/bjophthalmol-2017-31070928855196

Tania Gunn, Jane Easdown, E. Outerbridge, Jacob Aranda (1980)

Risk factors in retrolental fibroplasia.

Pediatrics, 65 6

(1991)

Retiriopathy of prematurity

The Lancet, 337

(2021)

The FIREFLEYE trial

Swedish national guidelines for screening and management of ROP 2021

(Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008;8:8. 10.1186/1471-2431-8-818307822)

Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008;8:8. 10.1186/1471-2431-8-818307822

Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008;8:8. 10.1186/1471-2431-8-818307822, Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008;8:8. 10.1186/1471-2431-8-818307822

G. Holmström, A. Hellström, Lotta Gränse, M. Saric, Birgitta Sunnqvist, A. Wallin, K. Tornqvist, E. Larsson (2019)

New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register

British Journal of Ophthalmology, 104

A. Niklasson, K. Albertsson-Wikland (2008)

Continuous growth reference from 24th week of gestation to 24 months by gender

BMC Pediatrics, 8

Lois Smith, A. Hellström, A. Stahl, A. Fielder, W. Chambers, Jane Moseley, C. Toth, D. Wallace, B. Darlow, J. Aranda, B. Hallberg, J. Davis (2019)

Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials

JAMA Ophthalmology, 137

CA Löfqvist, S Najm, G Hellgren (2018)

Association of retinopathy of prematurity with low levels of arachidonic acid: a secondary analysis of a randomized clinical trial

, 136

M. Odehnal, A. Filouš (1998)

[Retinopathy of prematurity].

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti, 54 1

(Hellström A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021;175:359–67. 10.1001/jamapediatrics.2020.565333523106)

Hellström A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021;175:359–67. 10.1001/jamapediatrics.2020.565333523106, Hellström A, Nilsson AK, Wackernagel D, et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 2021;175:359–67. 10.1001/jamapediatrics.2020.565333523106

(Swedish national guidelines for screening and management of ROP 2021, 2022. Available: https://www.medscinet.com/ROP/uploads/Nationella%20guidelines%20ROP-revidering%2016.12.2021.pdf [Accessed 23 Feb 2022].)

Swedish national guidelines for screening and management of ROP 2021, 2022. Available: https://www.medscinet.com/ROP/uploads/Nationella%20guidelines%20ROP-revidering%2016.12.2021.pdf [Accessed 23 Feb 2022]., Swedish national guidelines for screening and management of ROP 2021, 2022. Available: https://www.medscinet.com/ROP/uploads/Nationella%20guidelines%20ROP-revidering%2016.12.2021.pdf [Accessed 23 Feb 2022].

(Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. Am J Clin Nutr 2015;101:879–88. 10.3945/ajcn.114.09929125833984)

Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. Am J Clin Nutr 2015;101:879–88. 10.3945/ajcn.114.09929125833984, Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω-3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. Am J Clin Nutr 2015;101:879–88. 10.3945/ajcn.114.09929125833984

W. Tasman (2004)

Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Archives of ophthalmology, 121 12

(Pivodic A, Nilsson S, Stahl A, et al. Validation of the retinopathy of prematurity activity scale (ROP-ActS) using retrospective clinical data. Acta Ophthalmol 2021;99:201-206. 10.1111/aos.1453232592272)

Pivodic A, Nilsson S, Stahl A, et al. Validation of the retinopathy of prematurity activity scale (ROP-ActS) using retrospective clinical data. Acta Ophthalmol 2021;99:201-206. 10.1111/aos.1453232592272, Pivodic A, Nilsson S, Stahl A, et al. Validation of the retinopathy of prematurity activity scale (ROP-ActS) using retrospective clinical data. Acta Ophthalmol 2021;99:201-206. 10.1111/aos.1453232592272

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

References (45)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies